Cargando…

Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy

Infections are an important complication after B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy and risks may differ between the early and late periods. We evaluated infections in 99 adults who received a first BCMA–directed CAR T-cell therapy (commercial and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Little, Jessica S., Tandon, Megha, Hong, Joseph Seungpyo, Nadeem, Omar, Sperling, Adam S., Raje, Noopur, Munshi, Nikhil, Frigault, Matthew, Barmettler, Sara, Hammond, Sarah P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514400/ https://www.ncbi.nlm.nih.gov/pubmed/37486599 http://dx.doi.org/10.1182/bloodadvances.2023010524

Ejemplares similares

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
por: Watanabe, Keisuke, et al.
Publicado: (2023)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment
por: Panetti, Silvia, et al.
Publicado: (2022)

Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy
por: Jalota, Akansha, et al.
Publicado: (2022)

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells
por: Michelozzi, Ilaria M., et al.
Publicado: (2022)

Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation
por: Kim, Alexander B., et al.
Publicado: (2023)

Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden
por: Biondi, Marta, et al.
Publicado: (2023)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
por: Hirayama, Alexandre V., et al.
Publicado: (2022)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022)

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
por: Perriello, Vincenzo Maria, et al.
Publicado: (2022)

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023)

Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease
por: Kinoshita, Hannah, et al.
Publicado: (2022)

Dangerous B-cell clones
por: Greinacher, Andreas, et al.
Publicado: (2022)

T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome
por: Kumar, Deepak, et al.
Publicado: (2022)

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
por: Vogiatzi, Fotini, et al.
Publicado: (2022)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant
por: Jiang, Wei, et al.
Publicado: (2022)

Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8(+) T cells into B-cell follicles during HIV-1 infection
por: Ogunshola, Funsho J., et al.
Publicado: (2022)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia
por: Montironi, Chiara, et al.
Publicado: (2023)

Complementary HLH susceptibility factors converge on CD8 T-cell hyperactivation
por: Landy, Emily, et al.
Publicado: (2023)

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL
por: Diorio, Caroline, et al.
Publicado: (2022)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

TCRvβ-CART therapy mediates high-precision targeting of malignant T-cell clones
por: Shaw, Lauren C., et al.
Publicado: (2022)

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
por: Philipp, Nora, et al.
Publicado: (2022)

Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia
por: Shahid, Sanam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b62jsr6a72clj7jhvr517fcq4f